NextCure, Inc.

NXTC Healthcare Biotechnology

In the quarter to June 2026, EPS grew 75.2% and free cash flow grew 57.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

6.24 0.64 −9.30%
Market cap
$31.5M
P/E
0.0×
Fwd P/E
−2.4×
Dividend yield
—
F-score
n/a
Altman Z
14.11
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(195.22%) (132.40%) (111.23%) (116.91%)

+8 more TTM periods

ROA
(121.60%) (104.01%) (85.23%) (89.28%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(265.10%) (196.35%) (153.19%) (229.45%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(6.97) (9.54) (17.45) (18.29)
Free Cash Flow
(36.98) (49.98) (49.61) (48.94)
Other line items

Show all line items

Columns are period end dates